A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 234 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel June 28, 2021 运动对肺癌患者的益处 August 3, 2021 What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives January 26, 2024 Load more HOT NEWS The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not... More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease An unexpected find: clues about the genetics of children’s cancer found... Why haven’t we cured cancer? – That Cancer Conversation
